Latest Insider Transactions at Mineralys Therapeutics, Inc. (MLYS)
This section provides a real-time view of insider transactions for Mineralys Therapeutics, Inc. (MLYS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Mineralys Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Mineralys Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2023
|
Hbm Healthcare Investments (Cayman) Ltd. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,905,606
+37.46%
|
-
|
|
Feb 14
2023
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,250,000
+26.31%
|
$20,000,000
$16.0 P/Share
|
|
Feb 14
2023
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
1,928,476
+50.0%
|
-
|
|
Feb 14
2023
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
937,500
+17.18%
|
$15,000,000
$16.0 P/Share
|
|
Feb 14
2023
|
Srinivas Akkaraju |
BUY
Conversion of derivative security
|
Indirect |
3,581,861
+50.0%
|
-
|
|
Feb 14
2023
|
Adam Scott Levy CFO and Secretary |
BUY
Open market or private purchase
|
Direct |
6,250
+1.75%
|
$100,000
$16.0 P/Share
|
|
Feb 14
2023
|
Brian Taylor Slingsby Director |
BUY
Open market or private purchase
|
Indirect |
250,000
+2.65%
|
$4,000,000
$16.0 P/Share
|
|
Feb 14
2023
|
Brian Taylor Slingsby Director |
BUY
Conversion of derivative security
|
Indirect |
4,314,093
+32.54%
|
-
|